Compare VYX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | PVLA |
|---|---|---|
| Founded | 1881 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | VYX | PVLA |
|---|---|---|
| Price | $6.96 | $121.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $14.64 | ★ $161.13 |
| AVG Volume (30 Days) | ★ 2.2M | 322.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.46 | $18.23 |
| 52 Week High | $14.67 | $151.18 |
| Indicator | VYX | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 52.13 |
| Support Level | N/A | $85.53 |
| Resistance Level | $11.17 | $147.47 |
| Average True Range (ATR) | 0.44 | 9.83 |
| MACD | -0.07 | -1.98 |
| Stochastic Oscillator | 19.05 | 10.60 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.